Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 15, 2025International Journal of Cell and Biomedical ScienceOpen Access

hUC-MSCs Therapy with EVs Booster Improves Recovery in Stage 2 Chronic Kidney Disease with Hypercholesterolemia : a case report

View Full Paper
Ask AI
Bookmark
Share

Authors

JJutadiDADian AyuDCDini Cahyani

Discussion

Loading...

Member takes

Overview

Case report reveals improvement in serum lipid profile after hUC-MSC and secretome therapy, suggesting metabolic regulation. Findings indicate potential for addressing chronic kidney disease and hypercholesterolemia.

Key Points

  • Significant improvement in serum lipid profile was observed following hUC-MSC and secretome therapy.
  • Total cholesterol declined from 294 mg/dL to 225 mg/dL across two treatments, indicating benefits for metabolic regulation.
  • The therapy involved two intravenous cycles of hUC-MSC and secretome administered seven months apart.
  • These findings highlight the need for larger controlled trials to explore the underlying mechanisms of this therapeutic approach.

Cite This Study

Jutadi et al. (2025) studied this question.

synapsesocial.com/papers/68f02c7d616531447b5f93cehttps://doi.org/10.59278/cbs.v3i9.63
View Full Paper
Ask AI
Bookmark
Share